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Abstract 
Objective: Vulvar intraepithelial neoplasia (VIN) and vulvar Paget disease are managed with 
either vulvectomy, destructive treatments (laser, antimitotic drugs) or immunostimulants. All 
these options are associated with functional complications. The purpose of this study was to 
evaluate the surgical technique consisting of skinning vulvectomy with split-thickness skin 
graft, and its effect on overall quality of life and sexual function. 
Methods: a retrospective study was conducted on thirteen patients who underwent skinning 
vulvectomy with split-thickness skin graft between 1999 and 2009. Overall quality of life and 
sexual function were assessed with the Medical Outcome Study Short Form 36 (MOS SF-36) 
and Female Sexual Function Index (FSFI), respectively. 
Results: The median age of patients was 54 (range: 33-77) years. Three patients had Paget 
disease and 10 patients had VIN lesions. The excision margins were clear in 46% of cases. 
The incidence of occult cancer was 31% . The mean follow-up period was 77 (±35) months. 
Four patients experienced a relapse of their intraepithelial disease. The mean disease-free 
survival was 58 (±44) months. There was no significant difference in MOS SF-36 scores 
between the study population and the general population. The patients assessed with the FSFI 
regained normal sexual function after the surgical procedure. 
Conclusion: Skinning vulvectomy with split-thickness skin graft is a feasible technique 
yielding good results in terms of quality of life and sexual function. It enables occult cancer to 
be diagnosed in patients with VIN or Paget disease. 
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Introduction 
Vulvar intraepithelial neoplasia (VIN) causes pain and itching and can have major 
psychological and sexual repercussions. Incidence is low (5 new cases for 100,000 women 
worldwide 1) but has risen in developed countries (rise of 411% from 1973 to 2000), mainly 
affecting young women 2. The International Society for the Study of Vulvar Disease (ISSVD) 
divides VIN into usual-type VIN and differentiated-type VIN 3. Usual-type VIN affects 
women between the age of 30 and 50 and is strongly associated with high-risk HPV 4. 
Differentiated-type VIN affects older women often presenting lichen sclerosus. There is also 
vulvar Paget disease, which is an adenocarcinoma with intraepithelial development in the 
malpighian layer 5. VIN and Paget disease are intraepithelial lesions and can be associated 
with invasive lesions 6-8. Management of these lesions involves monitoring symptoms, 
preventing invasion and preserving normal vulvar anatomy and function. Radical local 
excision is the standard treatment as it enables histological analysis with detection of potential 
invasion but it often compromises vulvar anatomy with major repercussions on quality of life 
and sexual function 9 10. Destructive treatments (such as laser vaporization) 11 or 
immunostimulants (such as imiquimod) 12 13 have disadvantages, including local side effects 
and a lack of histological analysis of the full lesions. 
Split-thickness skin graft is a common reparative surgical technique 14. For patients with VIN 
or vulvar Paget disease, the skinning vulvectomy with a split-thickness skin graft appears to 
offer an interesting option for preventing the psychosexual disorders related to mutilating 
vulvar surgery. This surgical approach was described for the first time in 1968 15 then 
resumed in 1986 16. The technique has been little used and never been assessed at the 
functional level. 
The purpose of this study was to evaluate the surgical technique consisting of split-thickness 
skin graft after skinning vulvectomy, along with its impact on the overall quality of life and 
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sexual function of patients, as assessed with the Medical Outcome Study Short Form 36 
(MOS SF-36) questionnaire 17 and the Female Sexual Function Index (FSFI) 18.  
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Materials and methods 
Patients 
We conducted a retrospective cohort study on patients who underwent skinning vulvectomy 
with split-thickness skin graft. From the Department of Gynecology database we identified 
the cases of 13 women requesting skinning vulvectomy with split-thickness skin graft at 
Rennes Teaching Hospital between 1999 and 2009 from a total number of 226 vulvectomies 
(total, partial or skinning). The study was approved by the Institutional review board of the 
French college of obstetricians and gynecologists (CEROG-2010-26-R1) and informed 
consent was given by all the patients included. 
The outcome measures were the rate of cancer found at final pathological analysis of 
vulvectomy, quality of life and sexual function of patients.  
The medical records and outpatient records were reviewed. 
Surgical procedure 
After a preoperative diagnosis based on biopsy findings, the patients were operated on under 
general or regional anesthesia in the lithotomy position. The procedure was performed by a 
two-surgeon team including a gynecology surgeon and a plastic surgeon. It involved excision 
of the epidermis and the dermis extending beyond the lesions (≥ 5 mm) and preserving the 
subcutaneous tissue. The split-thickness skin graft was taken from the inner aspect of the 
thigh with a Braun air dermatome or a Dufourmentel surgical razor (0.012 in. thick). The graft 
was applied to the wound following vulvectomy. The surrounding edges were sutured with 
4/0 Vicryl absorbable sutures, achieving a tension-free closure. A bolster dressing was applied 
for 3 to 4 days to optimize adherence (Figure 1). We assessed postoperative pain according to 
both a visual analog scale (VAS) rated from 0 to 10 and postoperative analgesic requirements. 
Pathological analysis 
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Preoperative biopsy specimens were fixed in 10% formaldehyde and embedded in paraffin. 
Each biopsy was examined using multiple semi-serial sections. According to the established 
criteria (ISSVD) 3, we included cases of usual-type and differentiated-type VIN and Paget 
disease. The surgical resection specimens were oriented by the surgeon and sent fresh directly 
to the Pathology Department. They were pinned to a rigid board and fixed in 10% 
formaldehyde for 24 hours. All surgical margins were marked with India ink. The samples 
taken concerned the excision margins examined in full, the entire operative specimen 
examined in stages and the entire macroscopic lesion. The slides were reviewed by two 
pathologists (S.H. and Florence Burtin, MD).  
Functional assessment 
In December 2009, the patients were contacted for the study. They completed two validated 
instruments: the FSFI and a French validated translation of the MOS SF-36 17. The MOS SF-
36 is preferred for quality of life assessment instead of QLQC-30 (from European 
Organization for Research and Treatment of Cancer) or DLQI (Dermatology Life Quality 
Index) because of VIN or vulvar Paget disease are precancerous diseases (not cancer) and 
because of DLQI is a well known questionnaire for dermatologists but less known for others 
practitioners. For quality of life evaluation, the SF-36 questionnaire evaluates physical 
functioning, bodily pain, general health , vitality, social functioning, mental health, health 
transition and role-physical and role-emotional domains if patients have any problems with 
their work or other regular daily activities as a result of their physical health or any emotional 
problems, respectively. Each of the 36 items is scored on a 0-100 range, so that a high score 
defines a more favorable health state. All recorded items are averaged together to form the 
different scales for each of the eight mentioned specific domain. The scores obtained in 
studied population with the MOS SF-36 were compared with those of the reference French 
general female population 17 19. 
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FSFI is a well-validated, short and understandable instrument used to assess healthy women 
and women who have experienced vulvar excision 20. The FSFI measures five domains: 
desire, arousal, lubrication, orgasm, and pain on a scale of 2.0 to 36.0. A score strictly higher 
than 26 indicates normal sexual activity and a score of 26 or lower indicates sexual 
dysfunction 21. 
The both questionnaires provide exclusively self-report measures and do not include objective 
assessments by medical staff.  
Statistical analysis 
We used SAS (Statistical Analysis System) version 9.2 software. Continuous variables were 
compared with Student’s t-test and categorical variables were compared with the Chi 2 test or 
Fisher’s exact test, as appropriate. We used Student’s t-test which compares the mean value 
observed with a known mean of the reference population for the MOS SF-36 22. P values 
<0.05 were considered statistically significant. Progression-free survival was analyzed using 
the Kaplan-Meier method. 
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Results 
Epidemiological and clinical characteristics of the study population 
During the study period, 13 women referred for VIN or Paget disease underwent skinning 
vulvectomy with split-thickness skin graft. The median age of patients was 54 (range: 33-77) 
years. Body mass index median was 23 (range: 20-36) kg/m². Among the patients, 4 had a 
history of cervical disease, and 5 had a history of vulvovaginal disease, two of whom had 
undergone vulvar surgery. Six patients were smokers. Indications for performing skinning 
vulvectomy were usual-type VIN in 9 cases, differentiated-type VIN in one case and vulvar 
Paget disease in 3 cases determined from the preoperative biopsy (Table 1) 3. The patients’ 
symptoms were intense pruritus in 75% of cases, pain in 37% of cases and burning sensations 
in 12% of cases. Vulvar lesions measured 39 (range: 9-90) mm in diameter at their widest 
point and 22 (range: 10-40) mm in diameter at their narrowest point. The lesions were 
multifocal in 11 out of 13 cases and bilateral in 5 out of 13 cases.  
Surgical procedure and pathology data 
Median operating time was 80 (range: 60-120) minutes. Resection diameter was 65 (range: 
35-180) mm at its widest point and 60 (range: 23-130) mm at its narrowest point. The median 
hospital stay was 14 (range: 7-25) days. The maximum median pain assessed by the VAS was 
2 (range: 0-5) mm, 2 (range: 0-8) mm, 0 (range: 0-4) mm and 0 (range: 0-0) on the 1st, 2nd, 
5th and 10th day post-surgery, respectively. All patients received analgesics in the 
postoperative period: 46%, 61%, 54% and 13% of patients needed morphine on the 1st, 2nd, 
5th and 10th day post-surgery, respectively. 
The final histological examination of the operative specimen confirmed the preoperative 
diagnosis in all cases. The cases of usual-type VIN were multicentric in 7 cases out of 13 
patients. The margins were clear in 6 cases: 5 cases of VIN and 1 case of Paget disease. The 
lesion diameters measured 38 (range: 9-40) mm at their widest point for the patients with a 
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clear resection margin vs. 38 (range: 13-90) mm for the patients with an unclear resection 
margin (p=0.12). In 4 cases associated cancer was found: two cases were associated with 
usual-type VIN (invasive epidermoid carcinoma measuring 4.0 mm for one case and 2.8 mm 
for the other case) and two cases were associated with Paget disease (one case with 2 micro-
invasive adenocarcinomatous foci and one case with an 8 mm invasive adenocarcinoma). 
Macroscopic margins were >1 cm. The intraepithelial lesion diameters measured 39 (range: 
10-45) mm at their widest point for the patients with no associated cancer vs. 38 (range: 9-90) 
mm for the patients with associated cancer (p=0.68). For three of the patients with associated 
cancer adjuvant radiotherapy treatment was administered concomitantly, because of 
microscopic margin involvement. The fourth patient with associated cancer became pregnant 
in the postoperative follow-up period and gave birth to a live healthy child. She subsequently 
underwent unilateral inguinal curettage (no metastatic lymph node invasion) and did not 
receive radiotherapy. 
Follow-up and determinants of recurrence 
The mean follow-up period was 77 (±35) months. Mean disease-free survival for the 
population was 58 (±44) months (Figure 2). The disease-free survival rate was 73% at 2 years 
and 64% at 5 years. Four patients (31%) relapsed during follow-up. The mean time to 
recurrence was 19 (±13) months. All cases of recurrence were marked by the re-emergence of 
vulvar symptoms such as pruritus, burning sensation or pain. One patient experienced a 
relapse of Paget disease 16 months after surgery. One patient experienced a relapse of usual-
type VIN 10 months after surgery. Lastly, 2 patients relapsed with invasive disease 16 and 32 
months from surgery, respectively.  
Evaluation of quality of life and sexual function after skinning vulvectomy with split-thickness 
skin graft for vulvar intraepithelial neoplasia or vulvar Paget disease.  
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Among the 13 patients, 11 patients responded to the MOS SF-36 questionnaire. Scores for the 
SF-36 questionnaire are shown in Table 2. No significant difference was found when 
comparing the population that underwent skinning vulvectomy with split-thickness skin graft 
with the overall female population 19, regardless of the domain considered (Table 2). 
Among the 13 patients, 10 patients responded to the FSFI questionnaire assessing sexual 
function. Among the patients, 7 had no sexual activity, and their median age was 70 (38-77) 
years. The 3 patients who stated having sexual activity had a median age of 34 (33-40) years. 
Two patients had normal sexual activity with final scores of 31 and 32.4 for the FSFI. For 
these patients, the time between surgery and response to the questionnaire was 94 and 100 
months, and neither underwent radiotherapy or experienced relapse. The patient with sexual 
dysfunction (with a final FSFI score of 14.9) responded 61 months after surgery. She received 
radiotherapy following discovery of an invasive carcinoma post-surgery and subsequently had 
to undergo a left hemivulvectomy due to recurrence of the vulvar lesion. 
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Discussion 
Skinning vulvectomy with split-thickness skin graft in the case of VIN or vulvar Paget disease 
shows good results in terms of quality of life while allowing histological analysis of the entire 
lesions, thus enabling the screening of underlying invasive cancer. Although the study is not 
sufficient to answer the question about sexual disorders following a skinning vulvectomy, 
because of the sexual function could be assessed for only two patients, which presented 
normal sexual function.  
Occult cancers 
Our study has several limitations such as the retrospective character of the study with no 
functional assessment before the surgery, the small number of patients or some questionnaires 
administered many years after surgery. Nevertheless, our study provides interesting 
information about management of VIN or vulvar Paget disease. In our series, the skinning 
vulvectomy revealed 4 in 13 cases (31%) of cancer on the final operative specimen. In the 
literature, occult cancers were found on final histological analysis of the vulvectomy resection 
specimens in 3 to 22% of cases for VIN 11 16 23 24 and in 16% to 30% of cases for vulvar Paget 
disease 25 26. In our study, the higher incidence of occult cancer is probably due to the 
presence of large multifocal intraepithelial lesions.  
Recurrence of intraepithelial vulvar disease 
Secondly, recurrence is significantly linked to the size and multifocal nature of the lesions and 
to positive margins 6 7 11 24 27. The incidence of involved margins is 54% in our study, 
comparable with the published radical vulvectomy series which report involved margins of 
between 47% and 61% of VIN cases 6 7 24 and 54% of vulvar Paget disease cases 26 28. 
Regarding relapse of intraepithelial vulvar lesions, 31% of patients relapsed over a follow-up 
period of 77 (±35) months in our study, comparable with published surgical series which 
report a relapse rate of between 26% and 37% for VIN lesions 6 24 27 and 47% for vulvar Paget 
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lesions 5. The depth of skinning vulvectomy resection estimated at 5 mm (compared with a 15 
mm minimum thickness for a total vulvectomy) does not appear to negatively influence the 
risk of relapse which seems logical insofar as the lesions are strictly non-invasive. 
Quality of life and sexual function 
Data about quality of life and sexual function assessments after vulvar surgery are scarce in 
literature 9 10 29-31. Furthermore, the comparisons between published clinicopathological series 
are difficult because of the use of several tools for the assessment of quality of life: the 
European Organization for Research and Treatment of Cancer QLQ-C30 (QLQ C-30) scale 
was used by Likes and col 10 or de Melo Ferraira and col 30, or the MOS SF-36 by us or others 
31. The sexual function assessments suffers the same difficulties: DSM IV criteria were used 
by Green and al 9 and FSFI was used by us or others 10. Furthermore, scores were not always 
well reported: Likes et col reported correlations with FSFI score and clinicopathological data 
but they did not report the FSFI score itself 10. Nevertheless, the overall published data report 
that vulvectomy has a negative impact on sexual function and quality of life 29. Conversely, 
the skinning vulvectomy with split-thickness skin graft did not show negative impact in 
present study, but more studies are necessary to confirm this low side effect rate.  
Comparison between surgery and medical treatment 
The alternative to surgical resection of VIN or vulvar Paget disease lesions is destruction by 
CO2 laser vaporization 11, cryocoagulation 32 or imiquimod 7 8 11. Therapeutic vaccines for 
HPV 16 are currently undergoing clinical trials and may not as yet be recommended 33. The 
risk of relapse seems unrelated to treatment type for some authors 8 or not significantly 
different between surgical resection (26% of relapse) and imiquimod (14%), which are 
themselves significantly superior to destruction by laser (45% of relapse), for others 27. In a 
randomized trial of imiquimod vs. placebo, VIN lesions persisting after 1 year of treatment 
were observed in 15 out of 24 patients (62%) 12. Imiquimod is also recommended as treatment 
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for vulvar Paget disease 34-36. Imiquimod seems to offer advantages over surgical resection 
because of a risk of relapse that is potentially lower than surgery 27, probably due to the 
eradication of HPV 16, the causal agent of usual-type VIN 37. However, treatment by 
imiquimod has one major disadvantage in that it does not allow a full histological analysis of 
lesions (and hence invasive cancer may be overlooked), and has non-negligible side effects 
such as pain, itching and skin erosion 12. These side effects are all the more severe since the 
lesions are extensive and require application over several weeks 12 13. In our series, skinning 
vulvectomy with split-thickness skin graft can alleviate pain in a few days with a VAS of 0 on 
the 10th day post-surgery, while maintaining good functionality in terms of sexuality and 
quality of life in the long term once healing has occurred. 
 
Surgical technical aspect 
Of note, one of the limits of skinning vulvectomy with split-thickness skin graft is linked to 
the seat of the lesions as shown in our study. Posterior and lateral lesions are the site of 
predilection, whereas skin grafts are less likely to take on anterior lesions and in particular 
lesions of the clitoris. 
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Conclusion: 
The ideal treatment for VIN or vulvar Paget disease should be acceptable to patients, alleviate 
symptoms, enable diagnosis of possible invasion, eliminate the risk of relapse by performing 
full resection of lesions and removing the causal agent, and preserve quality of life (body 
image and sexuality in particular). Skinning vulvectomy with split-thickness skin graft fulfills 
a certain number of these objectives (acceptability and postoperative comfort, full analysis of 
lesions, possibility of wide excision margins), in particular in posterolateral lesions. However, 
given the high relapse rate observed, adjuvant treatments warrant investigation, in particular 
etiological treatments such as therapeutic vaccination 33 or immune response modulators that 
facilitate HPV clearance 37 in extended and multifocal forms. 
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Figure 1: Skinning vulvectomy with split-thickness skin graft surgical procedure 
 
Legends: a. Locating lesions and marking incision lines, b. Skinning vulvectomy, c. 
Operative specimen, d. Harvesting the graft, e. Graft, f. Placing the graft, g. Fixing the 
graft, h. Applying the bolster dressing 
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Table 1: Data of 13 patients having undergone skinning vulvectomy with split-thickness 
skin graft reconstruction. 
 
Pnt: patient; uVIN: Usual-type vulvar intraepithelial neoplasia; dVIN: differentiated-type 
vulvar intraepithelial neoplasia; K: cancer; DFS: disease-free survival 
Pnt Age 
(yrs) 
History 
of 
genital 
cancer 
Pre 
operative 
histology 
Post 
operative 
histology 
Multifocality Margins Adjuvant 
treatment 
Relapse D F S 
(months)
1 63 No uVIN uVIN + Clear None No 124 
2 66 No uVIN uVIN + + None No 112 
3 33 No uVIN uVIN+K + Clear Unilateral 
lymphadenectomy 
No 100 
4 50 No uVIN uVIN + Clear None No 99 
5 69 Yes Paget Paget + Clear None Yes 16 
6 37 No uVIN uVIN + Clear None No 94 
7 42 No uVIN uVIN + + None No 82 
8 34 No uVIN uVIN + + None Yes 10 
9 39 No uVIN uVIN +K -  + Radiotherapy Yes 39 
10 76 Yes dVIN dVIN + Clear None Yes 16 
11 71 No Paget Paget +K + + Radiotherapy No 48 
12 53 No uVIN uVIN + + None No 15 
13 62 No Paget Paget + K - + Radiotherapy No 4 
20 
 
Figure 2: Disease Free Survival Curve  
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Table 2: Quality of life of patients after skinning vulvectomy with split-thickness skin 
graft. 
SF36 domains Reference data Skinning vulvectomy with 
split-thickness skin graft 
p 
 Mean SD Mean SD  
Physical functioning 84.4 21.19 74.2 26.7 NS 
Role-physical 81.2 32.2 82.5 31.2 NS 
Bodily pain 73.3 23.7 68.4 21.5 NS 
General health 69.1 18.5 59.1 15.4 NS 
Vitality 59.9 18.0 59.5 17.2 NS 
Social functioning 81.5 21.4 82.5 12.0 NS 
Role-emotional 82.1 32.1 81.4 24.2 NS 
Mental health 68.4 17.6 71.6 11.3 NS 
NS: Not significant, SD: Standard deviation. 
 
 
 
